Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2013)
13 slides from Immuron's shareholder meeting presentation, Nov 29, 2013
Slide 1: Oral Immunotherapy Using Bovine Antibodies
For personal use only ORAL IMMUNOTHERAPY USING BOVINE ANTIBODIES
Slide 2: Forward-looking Statement
Forward-looking Statement For personal use only Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guida
Slide 3: 2013: The Achievements
2013: THE ACHIEVEMENTS For personal use only New Shareholders April rights issue: high networth investors who provide a lot of support Travelan: continue Direct-to-wholesale model in Australia, increase revenues commercialization Regulatory approval in Canada Regulatory progress in licensed
Slide 4: Looking Ahead
LOOKING AHEAD What we are seeking to achieve For personal use only Financial Strength Improve balance sheet Travelan: continue US Travelan transaction commercialization More licenses and more revenue Fatty Liver / NASH Commence Phase IIb Clinical trial Partner Progress RD Progress to the
Slide 5: Travelan: The last 3 years
For personal use only 0 1,000 2,000 3,000 4,000 5,000 6,000 Jan-10 Feb-10 Mar-10 Apr-10 TRAVELAN The last 3 years May-10 Jun-10 Jul-10 Aug-10 Sep-10 License with Takeda Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Jul-11 Aug-11 TRAVELAN Sep-11 Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar
Slide 6: Travelan: Before July 2013
R e t a I l e r s Wholesalers Before July 2013 TRAVELAN For personal use only
Slide 7: Travelan: Now (Australia)
TRAVELAN Now (Australia) For personal use only Immuron is commanding substantially higher margin R e t a I l e r s Wholesalers
Slide 8: Travelan: Going Forward
TRAVELAN Going Forward For personal use only Approved In Discussion In Discussion Various stages of ` regulatory ` process ` Licensed In Discussion ` In Revenue ` Proceeding through regulatory process
Slide 9: IMM-124E for NASH: Mechanism of Action
IMM-124E for NASH Mechanism of Action For personal use only Oral Immunotherapy: An approach to treating autoimmune, infectious and inflammatory disease through the oral delivery of antibodies There is continually growing scientific support for Immuron’s approach Immuron has the right product at the
Slide 10: IMM-124E for NASH: Ready to go: Phase 2B trial
IMM-124E for NASH Ready to go: Phase 2B trial For personal use only Based on existing technology: - Mature manufacturing process - High Safety profile IND cleared by the FDA: Immuron set to commence clinical trials Preparations under way Investigators identified IMM-124E has been independently valid
Slide 11: IMM-529 for Clostridium Difficile
IMM-529 for Clostridium Difficile For personal use only Clostridium difficile (C.diff): a bacteria normally found in people’s intestines • Certain circumstances C.diff can multiply and its toxin causes illness such as diarrhoea & severe inflammation of the bowel C. diff infection accounts for: • con
Slide 12: IMM-529 for Clostridium Difficile: Very encouraging results to date
IMM-529 for Clostridium Difficile Very encouraging results to date For personal use only • IMM-529 under collaboration with Monash University • All data owned by Immuron • IMM-529 demonstrated positive pre-clinical results: • Encouraging preventative data • Treatment effect currently being investiga
Slide 13: The Opportunity: Thank you
THE OPPORTUNITY For personal use only Thank you Contact Amos Meltzer – Chief Executive Officer 0437 587 680